Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2022 - 2026)

Zentalis Pharmaceuticals has reported Operating Expenses over the past 5 years, most recently at $37.9 million for Q1 2026.

  • For Q1 2026, Operating Expenses fell 17.03% year-over-year to $37.9 million; the TTM value through Mar 2026 reached $145.0 million, down 39.29%, while the annual FY2025 figure was $152.8 million, 40.91% down from the prior year.
  • Operating Expenses for Q1 2026 was $37.9 million at Zentalis Pharmaceuticals, up from $37.4 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $103.9 million in Q2 2023 and troughed at $33.7 million in Q3 2025.
  • A 5-year average of $57.4 million and a median of $57.9 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: skyrocketed 63.75% in 2023 and later plummeted 51.26% in 2025.
  • Year by year, Operating Expenses stood at $51.8 million in 2022, then soared by 31.24% to $67.9 million in 2023, then rose by 12.94% to $76.7 million in 2024, then plummeted by 51.26% to $37.4 million in 2025, then grew by 1.24% to $37.9 million in 2026.
  • Business Quant data shows Operating Expenses for ZNTL at $37.9 million in Q1 2026, $37.4 million in Q4 2025, and $33.7 million in Q3 2025.